Starting signal sounded: analytica 2012 to offer Early Bird discount

The starting signal has sounded for analytica 2012 in Munich. Application forms for the 23rd International Trade Fair for Laboratory Technology, Analysis and Biotechnology are available to interested companies. Also, a new offer is being introduced this year: For the first time ever, companies that register by January 31, 2011 will receive a five-percent Early Bird discount on selected stand space. Stand-space allocation for analytica 2012 was also moved forward considerably, i.e. to March 15, 2011.

"Preparations for analytica 2012 are already moving ahead at full speed. New application forms are now available," explains Susanne Grödl, Exhibition Director for analytica at Messe München. "As a result, things are moving along much earlier than in previous years, and we can offer our exhibitors an additional incentive: an Early Bird discount of five percent."

The discount applies to all stand space booked between September 1, 2010 and January 31, 2011, regardless of stand size and type (corner, row or island stand). The offer that is even worthwhile for smaller stands.

"The objective of this campaign is to give exhibitors an incentive to book their stand space early," adds Grödl. "After all, earlier registration allows us to move the entire planning process including visitor advertising considerably forward in time - which is something that exhibitors ultimately profit from."

Companies that do not automatically receive their application forms for the 2012 fair can download them directly at www.analytica.de/en/2012.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]